Scancell Company
Scancell is focused on developing innovative immunotherapies for cancer that stimulate the body’s own immune system.
Technology:
DNA, Atrificial Vectors and Immune Cells, Peptides and Proteins
Industry:
Covid-19
Headquarters:
Nottingham, Nottingham, United Kingdom
Founded Date:
1996-01-01
Employees Number:
11-50
Funding Status:
IPO
Investors Number:
5
Total Funding:
245000000
Estimated Revenue:
Less than $1M
Last Funding Date:
2016-08-04
Last Funding Type:
Post-IPO Equity
Register and Claim Ownership